Publications

@article{Ouoba2024,

title = {A new tool for assessing hepatitis B treatment eligibility in Africa},

author = {Serge Ouoba and Moussa Lingani},

url = {https://pubmed.ncbi.nlm.nih.gov/38367630/},

doi = {10.1016/S2468-1253(24)00006-2},

issn = {2468-1253},

year  = {2024},

date = {2024-01-01},

journal = {The lancet. Gastroenterology \& hepatology},

volume = {9},

issue = {4},

pages = {277-278},

publisher = {Lancet Gastroenterol Hepatol},

abstract = {Commercially available assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike (S) or anti-nucleocapsid (N) antibodies differ in units, making results comparisons challenging. This study aimed to develop conversion equations between five quantitative anti-S antibody tests and to assess the agreement over time between three qualitative anti-N antibody tests. Blood samples from 24 216 vaccinated healthcare workers in Hiroshima Prefecture, Japan, were analyzed for anti-S antibodies using five quantitative tests (Abbott, Fujirebio, Ortho, Sysmex, Roche) and for anti-N antibodies using three qualitative tests (Abbott, Sysmex, Roche). Geometric mean regression was performed to establish equations for converting measured values between the five quantitative tests. Fleiss κ statistic was used to assess the agreement between the three qualitative tests. A strong correlation (Pearson's coefficient r \> 0.9) was found for each pair of the five quantitative tests measuring anti-S antibodies, enabling the development of equations to convert values between each pair. Using these equations, which are based on the original output unit of each test, values obtained from one test can be transformed to be equivalent to the corresponding values in another test. For the three tests for anti-N antibodies, the agreement was substantial in the total sample (Fleiss' κ, 0.74) and moderate among those with self-reported past coronavirus disease 2019 (COVID-19) infection (Fleiss' κ, 0.39). The agreement decreased with time after infection. Reduced agreement between anti-N antibodies tests over time suggests caution in comparing seroepidemiological studies of COVID-19 exposure based on anti-N antibodies measurement. The findings could help improve antibody measurement systems and inform public health decision-makers.},

keywords = {Africa / epidemiology, Chronic* / diagnosis, Chronic* / drug therapy, Chronic* / epidemiology, Hepatitis B, Hepatitis B* / diagnosis, Hepatitis B* / drug therapy, Hepatitis B* / epidemiology, Humans, MEDLINE, Moussa Lingani, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, pmid:38367630, PubMed Abstract, Serge Ouoba},

pubstate = {published},

tppubtype = {article}

}

@article{Ouoba2023,

title = {Intermediate hepatitis B virus infection prevalence among 1622 pregnant women in rural Burkina Faso and implications for mother-to-child transmission},

author = {Serge Ouoba and Ko Ko and Moussa Lingani and Shintaro Nagashima and Alice N. Guingan\'{e} and E. Bunthen and Md Razeen Ashraf Hussain and Aya Sugiyama and Tomoyuki Akita and Masayuki Ohisa and Moussa Abdel Sanou and Ousmane Traore and Job Wilfried Nassa and Maimouna Sanou and Kazuaki Takahashi and Halidou Tinto and Junko Tanaka},

url = {https://pubmed.ncbi.nlm.nih.gov/37059812/},

doi = {10.1038/S41598-023-32766-3},

issn = {2045-2322},

year  = {2023},

date = {2023-01-01},

journal = {Scientific reports},

volume = {13},

issue = {1},

publisher = {Sci Rep},

abstract = {In highly endemic countries for hepatitis B virus (HBV) infection, childhood infection, including mother-to-child transmission (MTCT), represents the primary transmission route. High maternal DNA level (viral load ≥ 200,000 IU/mL) is a significant factor for MTCT. We investigated the prevalence of HBsAg, HBeAg, and high HBV DNA among pregnant women in three hospitals in Burkina Faso and assessed the performance of HBeAg to predict high viral load. Consenting pregnant women were interviewed on their sociodemographic characteristics and tested for HBsAg by a rapid diagnostic test, and dried blood spot (DBS) samples were collected for laboratory analyses. Of the 1622 participants, HBsAg prevalence was 6.5% (95% CI, 5.4\textendash7.8%). Among 102 HBsAg-positive pregnant women in DBS samples, HBeAg was positive in 22.6% (95% CI, 14.9\textendash31.9%), and viral load was quantified in 94 cases, with 19.1% having HBV DNA ≥ 200,000 IU/mL. HBV genotypes were identified in 63 samples and predominant genotypes were E (58.7%) and A (36.5%). The sensitivity of HBeAg by using DBS samples to identify high viral load in the 94 cases was 55.6%, and the specificity was 86.8%. These findings highlight the need to implement routine HBV screening and effective MTCT risk assessment for all pregnant women in Burkina Faso to enable early interventions that can effectively reduce MTCT.},

keywords = {Burkina Faso / epidemiology, Child, DNA, doi:10.1038/s41598-023-32766-3, Female, Hepatitis B e Antigens, Hepatitis B Surface Antigens, Hepatitis B virus / genetics, Hepatitis B* / diagnosis, Humans, Infectious Disease Transmission, Infectious* / epidemiology, Junko Tanaka, Ko Ko, MEDLINE, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Non-U.S. Gov't, PMC10103033, pmid:37059812, Pregnancy, Pregnancy Complications, Pregnant Women, Prevalence, PubMed Abstract, Research Support, Serge Ouoba, Vertical / prevention \& control, Viral / genetics},

pubstate = {published},

tppubtype = {article}

}